Wednesday's Analysts' Upgrades and Downgrades

E.W. Scripps (SSP Quote) downgraded at Goldman Sachs: Goldman is downgrading SSP to Neutral from Buy to reflect reduced near-term visibility and lower confidence that the company will take steps to reduce its exposure to the troubled newspaper industry. 2007 estimates cut to $2.41 from $2.53.

Tekelec (TKLC Quote) downgraded at UBS: TKLC downgraded to Hold rating from Buy at Jefferies. Price target drops to $16.75 from $17.50 with expected 2007 EPS at $0.55.

STOCK COMMENTS / EPS CHANGES

Align Technologies (ALGN Quote) numbers raised at Jefferies: ALGN numbers raised at Jefferies. Price target lifts to $14 from $11. 2007 EPS estimates jump to $0.17 from $0.05. Reiterates Hold rating.

Amylin Pharma (AMLN Quote) estimates lowered at Goldman: Goldman is cutting its 2007 estimates on AMLN to $(1.66) from $(1.02) due to higher operating expenses. Q4 results were inline with expectations. Maintained Buy rating and $59 target.

Burger King (BKC Quote) price target increased at Goldman: BKC target raised to $23 from $20 at Goldman. Company reiterated 2007 guidance, unit development goals, and 2007 same-store-sales targets of 2% to 3%. Expect continuing solid top line momentum to drive margins, despite labor, utilities and rent pressures. Maintained Neutral rating.

Countrywide (CFC Quote) estimates cut at Prudential: Prudential is cutting its 2007 estimates on CFC by 25 cents to $4.55 a share. Maintained Underweight rating.

Colgate-Palmolive (CL Quote) target increased at Goldman: Target on CL upped to $77 from $75 at Goldman. Company reported healthy Q5 results, including strength in margins and volume. Maintained Buy rating.

Walt Disney (DIS Quote) price target raised at Goldman: Goldman is increasing its target on DIS to $41 from $38 based on expectations for double-digit operating income growth through 2009. See increased syndication, stronger Studio performance, and an increase in Theme park attendance assumptions. Maintained Buy rating.

Electronics for Imaging (EFII Quote) numbers lowered at UBS: EFII numbers lowered at UBS. Price target drops to $30 from $32. 2007 EPS estimates bump down to $1.15 from $1.17. Reiterates Buy rating.